Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention

Sony Tuteja,Henry A Glick,William H. Matthai,Irving Nachamkin,Ashwin S. Nathan,Karen Monono,Craig Carcuffe,Karen Maslowski,Gene Chang,Taisei Kobayashi,Saif Anwaruddin,John W. Hirshfeld,Robert L. Wilensky,Howard C. Herrmann,Daniel M. Kolansky,Daniel J. Rader,Jay Giri

Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention

2020

Sony Tuteja
Henry A Glick
William H. Matthai
Irving Nachamkin
Ashwin S. Nathan
Karen Monono
Craig Carcuffe
Karen Maslowski
Gene Chang
Taisei Kobayashi
Saif Anwaruddin
John W. Hirshfeld
Robert L. Wilensky
Howard C. Herrmann
Daniel M. Kolansky
Daniel J. Rader
Jay Giri

Background: CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after percutaneous coronary intervention, but the clinical impact of implementing CYP2C19 genotyping in a real-world se...

Keywords:

Clinical trial
Clopidogrel
Genotyping
Precision medicine
Pharmacogenetics
Internal medicine
Percutaneous coronary intervention
CYP2C19
Medicine

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations